Literature DB >> 24465082

Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Yanqiao Zhang1.   

Abstract

Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily and plays an important role in maintaining bile acid, lipid and glucose homeostasis. Bile acids are endogenous ligands for FXR. However, bile acids may also activate pathways independent of FXR. The development of specific FXR agonists has provided important insights into the role of FXR in metabolism. Recent data have demonstrated that FXR is a therapeutic target for treatment of certain metabolic disorders. This review will focus on recent advances in the role of FXR in metabolic disease.

Entities:  

Year:  2010        PMID： 24465082      PMCID： PMC3899934          DOI： 10.1358/dof.2010.035.08.1520865

Source DB:  PubMed          Journal:  Drugs Future        ISSN： 0377-8282            Impact factor:   0.148


  88 in total

1.  Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway.

Authors:  S Gupta; R T Stravitz; P Dent; P B Hylemon
Journal:  J Biol Chem       Date:  2001-02-13       Impact factor: 5.157

2.  The bile acid sensor FXR regulates insulin transcription and secretion.

Authors:  Barbara Renga; Andrea Mencarelli; Piero Vavassori; Vincenzo Brancaleone; Stefano Fiorucci
Journal:  Biochim Biophys Acta       Date:  2010-01-07

3.  Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters.

Authors:  Stefan Bilz; Varman Samuel; Katsutaro Morino; David Savage; Cheol Soo Choi; Gerald I Shulman
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-11-15       Impact factor: 4.310

4.  The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes.

Authors:  Li Wang; Jun Liu; Pradip Saha; Jiansheng Huang; Lawrence Chan; Bruce Spiegelman; David D Moore
Journal:  Cell Metab       Date:  2005-10       Impact factor: 27.287

5.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice.

Authors:  Insook Kim; Keiichirou Morimura; Yatrik Shah; Qian Yang; Jerrold M Ward; Frank J Gonzalez
Journal:  Carcinogenesis       Date:  2006-12-20       Impact factor: 4.944

6.  Identification of a nuclear receptor for bile acids.

Authors:  M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

Review 7.  Endocrine functions of bile acids.

Authors:  Sander M Houten; Mitsuhiro Watanabe; Johan Auwerx
Journal:  EMBO J       Date:  2006-03-16       Impact factor: 11.598

8.  A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.

Authors:  Mark J Evans; Paige E Mahaney; Lisa Borges-Marcucci; KehDih Lai; Shuguang Wang; Julie A Krueger; Stephen J Gardell; Christine Huard; Robert Martinez; George P Vlasuk; Douglas C Harnish
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-08       Impact factor: 4.052

9.  Identification of a nuclear receptor that is activated by farnesol metabolites.

Authors:  B M Forman; E Goode; J Chen; A E Oro; D J Bradley; T Perlmann; D J Noonan; L T Burka; T McMorris; W W Lamph; R M Evans; C Weinberger
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

10.  Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters.

Authors:  Reid M Huber; Kathleen Murphy; Bowman Miao; John R Link; Mark R Cunningham; Mark J Rupar; Paul L Gunyuzlu; Thomas F Haws; Altaf Kassam; Francoise Powell; Gregory F Hollis; Peter R Young; Ranjan Mukherjee; Timothy C Burn
Journal:  Gene       Date:  2002-05-15       Impact factor: 3.688
View more
  1 in total

1.  Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice.

Authors:  Yang Xu; Fei Li; Munaf Zalzala; Jiesi Xu; Frank J Gonzalez; Luciano Adorini; Yoon-Kwang Lee; Liya Yin; Yanqiao Zhang
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.